Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 738,090 shares of the company’s stock after acquiring an additional 31,984 shares during the quarter. Franklin Resources Inc.’s holdings in Structure Therapeutics were worth $20,017,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of GPCR. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Structure Therapeutics by 45.1% in the fourth quarter. Principal Financial Group Inc. now owns 791,134 shares of the company’s stock valued at $21,456,000 after acquiring an additional 245,775 shares during the last quarter. American Century Companies Inc. grew its position in Structure Therapeutics by 12.3% in the fourth quarter. American Century Companies Inc. now owns 612,616 shares of the company’s stock worth $16,614,000 after acquiring an additional 67,325 shares during the period. Candriam S.C.A. increased its stake in Structure Therapeutics by 59.6% during the fourth quarter. Candriam S.C.A. now owns 215,421 shares of the company’s stock worth $5,842,000 after acquiring an additional 80,421 shares during the last quarter. Finally, Handelsbanken Fonder AB acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at $4,475,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

GPCR has been the subject of a number of recent analyst reports. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Down 7.4 %

Structure Therapeutics stock opened at $15.12 on Monday. Structure Therapeutics Inc. has a 52-week low of $14.88 and a 52-week high of $62.74. The firm has a market cap of $867.03 million, a PE ratio of -20.43 and a beta of -1.35. The company’s 50 day moving average is $23.03 and its two-hundred day moving average is $30.34.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. On average, equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.